Endovascular Intervention in the Treatment of Peripheral Artery Disease.

Endovascular therapy has emerged as an essential part of the management we can offer patients suffering from peripheral arterial disease. The AHA/ACCF guidelines deemed ballon angioplasty as a reasonable alternative for patients with limb threatening lower extremity ischemia who are not candidates for an autologus venous graft. Endovascular treatment is most useful for the treatment of critical limb ischemia and should ensure adequate proximal flow before engaging in interventions of distal disease.

Ventricular non-compaction cardiomyopathy.

Non-compaction of the left ventricle is an extremely rare cardiomyopathy resulting from a defective morphogenesis of the endomyocardium. It results in an architecturally aberrant ventricular wall consisting of two layers: a compacted layer and a loose interwoven meshwork with prominent trabeculae and deep intertrabecular recesses that communicate with the left ventricular cavity. This report describes the case of a 25-year-old man with dilated cardiomyopathy, due to non-compaction of the left ventricle, presenting with a transient ischemic attack.

Benign cardiac neoplasms: the experience at the Cardiovascular Center of Puerto Rico and the Caribbean.

Introduction: Neoplasms of the heart are extremely rare and difficult to diagnose. In this study, we intend to describe the experience at the Cardiovascular Center of Puerto Rico and the Caribbean (CCPRC) dealing with benign cardiac neoplasms.

Methods: A retrospective review of the archival material at our institution was conducted using the 2007 ICD-9-CM code 212.

Percutaneous coronary intervention: the story so far.

Over the past two decades, the use of percutaneous coronary intervention (PCI) to treat ischemic coronary artery disease (CAD) has expanded dramatically. With new technological improvements (e.g.

Percutaneous coronary intervention versus thrombolysis: the definite management of st elevation myocardial infarction.

The management of an ST elevation myocardial infarction has undergone significant changes in the past few years. Fibrinolytic agents have become more and more clot specific increasing their efficacy. However, percutaneous coronary intervention, along with its adjuvant therapy (glycoprotein IIB/IIIA receptor inhibitors and clopidrogel), have come to challenge fibrinolytic use.